-

CORRECTING and REPLACING Newomics Announces Collaborations on High-throughput Bioanalysis

CORRECTION...by Newomics Inc.

BERKELEY, Calif.--(BUSINESS WIRE)--Please replace the release dated March 2, 2022 with the following corrected version due to multiple revisions.

The updated release reads:

NEWOMICS ANNOUNCES COLLABORATIONS ON HIGH-THROUGHPUT BIOANALYSIS

Newomics Inc., a biotechnology company commercializing mass spectrometry solutions for molecular detection, today announced collaborations with Bruker Corporation, a company with differentiated high-value life science research and diagnostics solutions, on a novel LC-MS platform for drug discovery in the Pharma/Biopharma industry as well as research institutions.

The two companies agreed on co-marketing Newomics’s Microflow-nanospray Electrospray Ionization (MnESI) product line with Bruker’s maxis II and timsTOF Pro 2 mass spectrometers. The joint MnESI-MS platform offers unmatched isotopic fidelity, sensitivity, robustness, and reproducibility for high-throughput analysis of small volumes of biological samples.

“This co-marketing agreement is built upon close collaborations between our R&D teams over the last several years. We look forward to working with Newomics to create workflows using MnESI products on Bruker mass spectrometers for biologics and native mass spec applications,” said Michael Greig, Director, Pharma/Biopharma Americas at Bruker.

“We are excited to expand our successful collaborations with Bruker,” said Daojing Wang, Ph.D., Newomics Founder and CEO. “Our M3 emitter is the first commercial multinozzle emitter for mass spectrometry. The new MnESI source directly addresses several key pain points in mass spectrometry analysis of native proteins, protein complexes, and oligonucleotides, and opens up new opportunities for biopharmaceutical and clinical research and development.”

More information about the MnESI Products is available here.

About Newomics Inc.

Newomics Inc. is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The company’s products deliver the robustness of microflow LC and the sensitivity of nanospray ionization MS. The plug-and-play MnESI platform is currently interfaced to diverse MS instruments and can be ordered at www.newomics.com.

Contacts

Sophie Bianchi
Newomics Inc.
617-335-4612
sbianchi@newomics.com

NEWOMICS

Details
Headquarters: Berkeley, CA
CEO: Daojing Wang
Employees: 10
Organization: PRI

Release Versions

Contacts

Sophie Bianchi
Newomics Inc.
617-335-4612
sbianchi@newomics.com

More News From NEWOMICS

Newomics Inc. Places Its 100th Mass Spectrometry Front-end System

BERKELEY, Calif.--(BUSINESS WIRE)--Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics such as Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research. The system is made up of an ion source integrated with breakthrough silicon microfluidic chips including M3 em...

Newomics Announces Sales Team and New Kits

BERKELEY, Calif.--(BUSINESS WIRE)--Newomics Inc., a biotechnology company developing and commercializing mass spectrometry solutions, today announced that it has established a North America Sales Team, and it is launching a new product to enhance the existing mass spectrometry workflows. Newomics continues its dedication to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The MnESI platform (M3 multinozzle emitter + MnESI sour...

Newomics Closes $7.9 Million Series B Financing to Accelerate Growth

BERKELEY, Calif.--(BUSINESS WIRE)--Newomics Closes $7.9 Million Series B...
Back to Newsroom